7-甲氧基-四氢萘-2-甲酸甲酯 | 65844-56-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 7-甲氧基-四氢萘-2-甲酸甲酯
• 英文名称: methyl 1,2,3,4-tetrahydro-7-methoxy-2-naphthalenecarboxylate
• 英文别名: methyl 7-methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylate；methyl 7-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate；3-carbomethoxy-6-methoxy-1,2,3,4-tetrahydronaphthalene；methyl 7-methoxy-1,2,3,4-tetrahydro-(2R)-2-naphthoate
• CAS: 65844-56-6
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: LGHVETGTLVYZEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  7-甲氧基-四氢萘-2-甲酸甲酯 在 氢溴酸 、 溶剂黄146 作用下， 以87%的产率得到7-羟基-1,2,3,4-四氢-萘-2-羧酸
  参考文献：
  名称：

  Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors

  摘要：

  Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

  DOI：

  10.1021/jm101479y
• 作为产物：
  描述：

  7-甲氧基-1-萘满酮 在 硫酸 、 palladium on activated charcoal 、 氢气 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 水 、 mineral oil 为溶剂， 65.0 ℃ 、101.33 kPa 条件下， 反应 26.0h， 生成 7-甲氧基-四氢萘-2-甲酸甲酯
  参考文献：
  名称：

  Regioselective Dearomative Amidoximation of Nonactivated Arenes Enabled by Photohomolytic Cleavage of N‐nitrosamides

  摘要：

  摘要脱芳基螺环化反应是将烷烃转化为三维结构的一种很有前景的方法；然而，控制非活化烷烃脱芳基反应的区域选择性，以获得螺环化的 1,2-二官能度，而不是其动力学上偏好的 1,4-二官能度，却极具挑战性。在这里，我们揭示了一种新策略，即通过可见光直接诱导亚硝酰胺的 N-NO 键的均裂，实现（杂）烷的 1,2- 或 1,4- 氨基肟化，从而产生各种高区域选择性的氨基肟化螺环，而这些螺环以前是无法获得的，或者需要精心的合成工作。通过对照实验和密度泛函理论计算，研究了观察到的区域选择性的机理和起源。

  DOI：

  10.1002/anie.202317968

文献信息

• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Calderwood Emily F.

  公开号：US20120015942A1

  公开（公告）日：2012-01-19

  This invention provides compounds of formula (I): wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 2c , and R 2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  这项发明提供了式（I）的化合物： 其中R1a、R1b、R1c、R2a、R2b、R2c和R2d的取值如规范中所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗增殖性、炎症性、感染性、神经系统或心血管疾病或紊乱中使用这些组合物的方法。
• [EN] DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS<br/>[FR] DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE ET COMPOSÉS APPARENTÉS ET LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS MÉDICAUX
  申请人：LYCERA CORP

  公开号：WO2019200120A1

  公开（公告）日：2019-10-17

  The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

  这项发明提供了二氢异喹啉-2(1H)-甲酰胺及相关化合物、药物组合物，以及它们在治疗医疗状况（如癌症）和抑制HPK1活性中的用途。
• Di-and tetrahydronapthyl anti-allergy agents
  申请人：G.D. Searle & Co.

  公开号：EP0300404A3

  公开（公告）日：1990-07-18

  This invention relates to compounds of the formula: and the pharmaceutically acceptable salts thereof: wherein R¹ represents straight or branched chain alkyl having 2-4 carbon atoms; wherein R² represents hydrogen or straight or branched chain alkyl having 1-6 carbon atoms; wherein R³ represents hydrogen or straight or branched chain alkyl having 1-3 carbon atoms; wherein R⁴ and R¹⁰ are different and represent H or n-propyl; wherein X represents an interger from 2 to 5; wherein R⁵ is hydrogen, or acts with R⁷ to produce an additional carbon-­carbon bond between C₁ and C₂; wherein R⁶ represents hydrogen or -Z-COOR⁹, wherein Z is either absent or represents straight or branched chain alkyl or alkenyl having 1-5 carbon atoms; and R⁹ represents hydrogen, pharmaceutically acceptable cations, or straight or branched chain alkyl having 1-6 carbon atoms; wherein R⁷ is hydrogen, or acts together with R⁵ to form an additional carbon-carbon bond between C₁ and C₂, or acts together with R⁸ to form when R⁸ is oxygen; wherein R⁸ is hydrogen, -O-R¹¹, or oxygen, such that when R⁸ is oxygen, R⁸ acts together with R⁷ to form and wherein R¹¹ is straight or branched chain alkyl having 1-4 carbon atoms. The di- and tetrahydronaphthyl compounds of this invention are pharmacologically active as leukotriene D₄ (LTD₄) antagonists and are useful as anti-­inflammatory and anti-allergy agents.

  本发明涉及以下化合物的公式：及其药学上可接受的盐：其中R¹代表具有2-4个碳原子的直链或支链烷基；其中R²代表氢或具有1-6个碳原子的直链或支链烷基；其中R³代表氢或具有1-3个碳原子的直链或支链烷基；其中R⁴和R¹⁰不同，代表H或正丙基；其中X代表从2到5的整数；其中R⁵为氢，或与R⁷作用以在C₁和C₂之间产生额外的碳-碳键；其中R⁶代表氢或-Z-COOR⁹，其中Z要么不存在，要么代表具有1-5个碳原子的直链或支链烷基或烯烃基；R⁹代表氢、药学上可接受的阳离子，或具有1-6个碳原子的直链或支链烷基；其中R⁷为氢，或与R⁵一起作用以在C₁和C₂之间形成额外的碳-碳键，或与R⁸一起作用当R⁸为氧时；其中R⁸为氢、-O-R¹¹，或氧，当R⁸为氧时，R⁸与R⁷一起形成，其中R¹¹为具有1-4个碳原子的直链或支链烷基。本发明的二氢和四氢萘基化合物在药理学上作为白三烯D₄（LTD₄）拮抗剂具有药理活性，并可用作抗炎和抗过敏药剂。
• Enzymatic process for the preparation of optically active tetralin
  申请人：Sanofi

  公开号：US05719308A1

  公开（公告）日：1998-02-17

  The present invention relates to an enzymatic process for the preparation of optically active tetrahydro-2-naphthoic acids from the corresponding racemic esters by reaction with a lipase.

  本发明涉及一种酶法制备对映活性四氢-2-萘甲酸的方法，通过与脂肪酶反应将相应的外消旋酯转化而来。
• Enzymatic process for the preparation of optically active
  申请人：Sanofi

  公开号：US05573949A1

  公开（公告）日：1996-11-12

  The present invention relates to an enzymatic process for the preparation of optically active tetrahydro-2-naphthoic acids from the corresponding racemic esters by reaction with a lipase.

  本发明涉及一种用酶法从相应的外消旋酯经与脂肪酶反应制备光学活性四氢-2-萘酸的方法。